sigma pharmaceuticals plc

4.5

sigma pharmaceuticals plc Company Information

Share SIGMA PHARMACEUTICALS PLC
Live 
MatureMegaHealthy

Company Number

01561802

Registered Address

fifth floor watson house, 54-60 baker street, london, W1U 7BU

Industry

Wholesale of pharmaceutical goods

 

Telephone

08003584427

Next Accounts Due

February 2025

Group Structure

View All

Directors

Hatul Shah13 Years

Bhavin Shah13 Years

View All

Shareholders

orion holdings (uk) limited 33.3%

bharat kumar shah 22.2%

View All

sigma pharmaceuticals plc Estimated Valuation

£268.7m

Pomanda estimates the enterprise value of SIGMA PHARMACEUTICALS PLC at £268.7m based on a Turnover of £248m and 1.08x industry multiple (adjusted for size and gross margin).

sigma pharmaceuticals plc Estimated Valuation

£155.4m

Pomanda estimates the enterprise value of SIGMA PHARMACEUTICALS PLC at £155.4m based on an EBITDA of £16m and a 9.7x industry multiple (adjusted for size and gross margin).

sigma pharmaceuticals plc Estimated Valuation

£78.5m

Pomanda estimates the enterprise value of SIGMA PHARMACEUTICALS PLC at £78.5m based on Net Assets of £37.8m and 2.08x industry multiple (adjusted for liquidity).

Valuation Calculator
This valuation is estimated based on financial data from August 2023 

Sigma Pharmaceuticals Plc AI Business Plan

In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.

View Sample

Sigma Pharmaceuticals Plc Overview

Sigma Pharmaceuticals Plc is a live company located in london, W1U 7BU with a Companies House number of 01561802. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in May 1981, it's largest shareholder is orion holdings (uk) limited with a 33.3% stake. Sigma Pharmaceuticals Plc is a mature, mega sized company, Pomanda has estimated its turnover at £248m with healthy growth in recent years.

View Sample
View Sample
View Sample

Upgrade for unlimited company reports & a free credit check

Sigma Pharmaceuticals Plc Health Check

Pomanda's financial health check has awarded Sigma Pharmaceuticals Plc a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 4 areas for improvement. Company Health Check FAQs

Health Check Image
Health Rating4.5out of 5
positive_score

6 Strong

positive_score

2 Regular

positive_score

4 Weak

size

Size

annual sales of £248m, make it larger than the average company (£24.8m)

£248m - Sigma Pharmaceuticals Plc

£24.8m - Industry AVG

growth

Growth

3 year (CAGR) sales growth of 4%, show it is growing at a similar rate (4.8%)

4% - Sigma Pharmaceuticals Plc

4.8% - Industry AVG

production

Production

with a gross margin of 19.3%, this company has a higher cost of product (25.1%)

19.3% - Sigma Pharmaceuticals Plc

25.1% - Industry AVG

profitability

Profitability

an operating margin of 6.1% make it more profitable than the average company (3.7%)

6.1% - Sigma Pharmaceuticals Plc

3.7% - Industry AVG

employees

Employees

with 430 employees, this is above the industry average (38)

430 - Sigma Pharmaceuticals Plc

38 - Industry AVG

paystructure

Pay Structure

on an average salary of £33k, the company has a lower pay structure (£73.6k)

£33k - Sigma Pharmaceuticals Plc

£73.6k - Industry AVG

efficiency

Efficiency

resulting in sales per employee of £576.8k, this is equally as efficient (£671k)

£576.8k - Sigma Pharmaceuticals Plc

£671k - Industry AVG

debtordays

Debtor Days

it gets paid by customers after 85 days, this is later than average (63 days)

85 days - Sigma Pharmaceuticals Plc

63 days - Industry AVG

creditordays

Creditor Days

its suppliers are paid after 60 days, this is slower than average (31 days)

60 days - Sigma Pharmaceuticals Plc

31 days - Industry AVG

stockdays

Stock Days

it holds stock equivalent to 45 days, this is less than average (64 days)

45 days - Sigma Pharmaceuticals Plc

64 days - Industry AVG

cashbalance

Cash Balance

has cash to cover current liabilities for 3 weeks, this is less cash available to meet short term requirements (9 weeks)

3 weeks - Sigma Pharmaceuticals Plc

9 weeks - Industry AVG

debtlevel

Debt Level

it has a ratio of liabilities to total assets of 63.1%, this is a higher level of debt than the average (57.1%)

63.1% - Sigma Pharmaceuticals Plc

57.1% - Industry AVG

sigma pharmaceuticals plc Credit Report and Business Information

Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for sigma pharmaceuticals plc. Get real-time insights into sigma pharmaceuticals plc's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Sigma Pharmaceuticals Plc Competitor Analysis

BETA
competitor_analysis_table_img

Perform a competitor analysis for sigma pharmaceuticals plc by selecting its closest rivals and benchmarking them against 12 key performance metrics.

sigma pharmaceuticals plc Ownership

SIGMA PHARMACEUTICALS PLC group structure

Sigma Pharmaceuticals Plc has no subsidiary companies.

Ultimate parent company

SIGMA PHARMACEUTICALS PLC

01561802

SIGMA PHARMACEUTICALS PLC Shareholders

orion holdings (uk) limited 33.32%
bharat kumar shah 22.23%
manish hansraj shah 22.23%
kamal kumar hansraj shah 22.23%

sigma pharmaceuticals plc directors

Sigma Pharmaceuticals Plc currently has 7 directors. The longest serving directors include Mr Hatul Shah (Mar 2011) and Mr Bhavin Shah (Mar 2011).

officercountryagestartendrole
Mr Hatul ShahUnited Kingdom45 years Mar 2011- Director
Mr Bhavin ShahUnited Kingdom40 years Mar 2011- Director
Mr Rajiv ShahEngland39 years Mar 2011- Director
Mr Paras ShahUnited Kingdom36 years Nov 2014- Director
Mr Rajesh HariaEngland59 years Apr 2020- Director
Mr James MoirUnited Kingdom59 years Apr 2022- Director
Mr Mark HamptonUnited Kingdom59 years Jul 2022- Director

SIGMA PHARMACEUTICALS PLC financials

EXPORTms excel logo

Sigma Pharmaceuticals Plc's latest turnover from August 2023 is £248 million and the company has net assets of £37.8 million. According to their latest financial statements, Sigma Pharmaceuticals Plc has 430 employees and maintains cash reserves of £2.6 million as reported in the balance sheet.

Data source: Companies HousePomanda Estimates

Aug 2023Aug 2022Aug 2021Aug 2020Aug 2019Aug 2018Aug 2017Aug 2016Aug 2015Aug 2014Aug 2013Aug 2012Aug 2011Aug 2010Aug 2009
Turnover248,028,130207,670,692214,717,036220,380,612227,012,613248,481,927253,479,235240,442,000241,824,000232,783,105214,903,208177,124,619213,017,541218,212,601165,070,566
Other Income Or Grants000000000000000
Cost Of Sales200,130,938174,936,157186,894,646194,555,849199,533,212222,688,317226,129,834215,102,000219,053,000210,586,737193,652,189159,389,399191,960,830198,592,923148,655,260
Gross Profit47,897,19232,734,53527,822,39025,824,76327,479,40125,793,61027,349,40125,340,00022,771,00022,196,36821,251,01917,735,22021,056,71119,619,67816,415,306
Admin Expenses32,683,94727,376,66826,856,68325,690,52925,794,79724,958,57522,963,67422,986,00020,160,00019,541,67418,883,23016,026,41018,510,37516,847,36614,397,150
Operating Profit15,213,2455,357,867965,707134,2341,684,604835,0354,385,7272,354,0002,611,0002,654,6942,367,7891,708,8102,546,3362,772,3122,018,156
Interest Payable2,165,088778,071676,869759,948841,216769,292769,338752,000637,000740,645634,709678,862670,692666,547723,099
Interest Receivable0266,91018,85439,02918,10015,23819,07833,00015,00018,6967,22014,68572212,421
Pre-Tax Profit12,783,1734,846,706550,327-806,394746,71478,8213,635,4671,635,0001,989,0001,932,7451,740,3001,055,3581,875,7162,105,7861,297,478
Tax-2,847,150-297,80260,869149,270-477,476547,878-763,064-303,000-180,000-435,383-850,704-269,536-558,748-660,987-460,640
Profit After Tax9,936,0234,548,904611,196-657,124269,238626,6992,872,4031,332,0001,809,0001,497,362889,596785,8221,316,9681,444,799836,838
Dividends Paid672,225000009,000450,000968,0000000900,0000
Retained Profit9,263,7984,548,904611,196-657,124269,238626,6992,863,403882,000841,0001,497,362889,596785,8221,316,968544,799836,838
Employee Costs14,174,35412,834,96412,870,49810,844,76910,721,92010,631,96810,256,1629,893,0008,273,0007,762,0527,144,1146,481,5666,241,8465,794,3295,298,788
Number Of Employees430391360339311308328318306234270260248244219
EBITDA*16,021,9826,106,8771,717,9501,017,7602,505,8541,779,8665,367,2812,590,0002,827,0002,865,0192,624,0652,002,4912,809,6412,986,8412,206,456

* Earnings Before Interest, Tax, Depreciation and Amortisation

Aug 2023Aug 2022Aug 2021Aug 2020Aug 2019Aug 2018Aug 2017Aug 2016Aug 2015Aug 2014Aug 2013Aug 2012Aug 2011Aug 2010Aug 2009
Tangible Assets8,698,6118,789,8318,825,0898,720,4999,071,63713,898,2589,012,4343,036,0002,426,0002,534,805581,778693,288600,544479,270440,006
Intangible Assets0264,98400301,931476,931705,603886,000140,00033,15938,31387,810150,396213,521169,961
Investments & Other180,000282,000282,000282,000282,000282,000282,000282,000282,000282,000282,000282,000327,000327,00045,000
Debtors (Due After 1 year)0000004,953,5244,497,0004,196,0003,858,1557,049,3778,900,54910,367,2640934,988
Total Fixed Assets8,878,6119,336,8159,107,0898,720,4999,373,56814,375,18914,953,5618,701,0007,044,0006,708,1197,951,4689,963,64711,445,2041,019,7911,589,955
Stock & work in progress25,000,96924,114,82732,078,19336,285,62042,977,73933,002,55836,279,45138,949,00034,502,00031,603,36733,035,56937,508,00542,362,30645,066,39735,541,591
Trade Debtors58,293,56353,880,97449,183,11048,671,82147,211,31447,199,42146,624,73145,406,00050,814,00047,626,56945,237,66935,616,77635,011,32940,864,12234,593,209
Group Debtors3,438,1173,382,9544,757,3167,258,6527,401,79002,789,9872,848,0002,911,0006,208,2014,595,8613,596,8172,170,4891,559,1471,578,615
Misc Debtors4,178,9832,705,4072,754,4221,103,3452,632,8265,117,4952,007,8831,664,000981,000281,372440,967730,3323,561,1421,319,208969,039
Cash2,598,6943,153,3411,522,8595,690,8261,343,1702,156,4183,891,2014,534,0001,882,0009,125,9775,805,7323,407,3412,182,4931,644,1322,230,523
misc current assets000000000000000
total current assets93,510,32687,237,50390,295,90099,010,264101,566,83987,475,89291,593,25393,401,00091,090,00094,845,48689,115,79880,859,27185,287,75990,453,00674,912,977
total assets102,388,93796,574,31899,402,989107,730,763110,940,407101,851,081106,546,814102,102,00098,134,000101,553,60597,067,26690,822,91896,732,96391,472,79776,502,932
Bank overdraft00000030,132,52831,086,00024,813,00030,499,94025,586,77622,969,58224,264,04627,408,76120,916,515
Bank loan96,10732,413,34538,404,00139,250,89637,774,91001,672,98000000000
Trade Creditors 32,921,68229,219,51632,082,74830,975,54438,934,79931,593,34434,942,44435,236,00038,714,00033,845,47534,525,91030,900,47632,906,03836,031,26929,627,611
Group/Directors Accounts302,828143,42100005007,0004,00006,4286,4281,454296296
other short term finances230,80200000000000000
hp & lease commitments054,319227,826277,766374,761367,39774,71015,00013,00015,87116,86912,11502,02826,418
other current liabilities8,931,9286,220,2374,228,35310,477,6055,508,30235,493,6373,580,9203,541,0004,134,0008,216,7496,053,0534,775,9745,221,2364,009,6172,454,037
total current liabilities42,483,34768,050,83874,942,92880,981,81182,592,77267,454,37870,404,08269,885,00067,678,00072,578,03566,189,03658,664,57562,392,77467,451,97153,024,877
loans22,110,587001,091,1583,096,0146,694,1724,999,0751,562,000972,000000000
hp & lease commitments29,78222,05782,750310,579549,007842,581274,96365,00017,00019,48734,71233,130002,028
Accruals and Deferred Income00000000003,000,7986,001,5979,002,39500
other liabilities00424,7920000356,000115,000445,508829,5080000
provisions000121,73800000000000
total long term liabilities22,140,36922,057507,542606,4481,548,0073,347,0865,274,0381,983,0001,104,000464,9953,865,0186,034,7279,002,39502,028
total liabilities64,623,71668,072,89575,450,47081,588,25984,140,77970,801,46475,678,12071,868,00068,782,00073,043,03070,054,05464,699,30271,395,16967,451,97153,026,905
net assets37,765,22128,501,42323,952,51926,142,50426,799,62831,049,61730,868,69430,234,00029,352,00028,510,57527,013,21226,123,61625,337,79424,020,82623,476,027
total shareholders funds37,765,22128,501,42323,952,51926,142,50426,799,62831,049,61730,868,69430,234,00029,352,00028,510,57527,013,21226,123,61625,337,79424,020,82623,476,027
Aug 2023Aug 2022Aug 2021Aug 2020Aug 2019Aug 2018Aug 2017Aug 2016Aug 2015Aug 2014Aug 2013Aug 2012Aug 2011Aug 2010Aug 2009
Operating Activities
Operating Profit15,213,2455,357,867965,707134,2341,684,604835,0354,385,7272,354,0002,611,0002,654,6942,367,7891,708,8102,546,3362,772,3122,018,156
Depreciation808,737749,010752,243581,595646,250769,831786,547172,000183,000185,171192,245231,095200,180158,089145,175
Amortisation000301,931175,000175,000195,00764,00033,00025,15464,03162,58663,12556,44043,125
Tax-2,847,150-297,80260,869149,270-477,476547,878-763,064-303,000-180,000-435,383-850,704-269,536-558,748-660,987-460,640
Stock886,142-7,963,366-4,207,427-6,692,1199,975,181-3,276,893-2,669,5494,447,0002,898,633-1,432,202-4,472,436-4,854,301-2,704,0919,524,80635,541,591
Debtors5,941,3283,274,487-338,970-212,1124,929,014-4,059,2091,961,125-4,487,000927,703650,4238,479,400-2,265,7507,367,7475,666,62638,075,851
Creditors3,702,166-2,863,2321,107,204-7,959,2557,341,455-3,349,100-293,556-3,478,0004,868,525-680,4353,625,434-2,005,562-3,125,2316,403,65829,627,611
Accruals and Deferred Income2,711,6911,991,884-6,249,2524,969,303-29,985,33531,912,71739,920-593,000-4,082,749-837,102-1,723,720-3,446,06010,214,0141,555,5802,454,037
Deferred Taxes & Provisions00-121,738121,73800000000000
Cash flow from operations12,761,2199,626,6061,061,4305,203,047-35,519,69738,227,4635,059,005-1,744,000-393,5601,693,878-331,8893,401,3844,676,020-4,906,340-39,789,978
Investing Activities
capital expenditure-452,533-978,736-856,833-230,4574,180,371-5,601,983-6,837,361-1,806,000-215,000-2,158,198-95,269-316,231-319,755-301,870-33,578
Change in Investments-102,0000000000000-45,0000282,00045,000
cash flow from investments-350,533-978,736-856,833-230,4574,180,371-5,601,983-6,837,361-1,806,000-215,000-2,158,198-95,269-271,231-319,755-583,870-78,578
Financing Activities
Bank loans-32,317,238-5,990,656-846,8951,475,98637,774,910-1,672,9801,672,98000000000
Group/Directors Accounts159,407143,421000-500-6,5003,0004,000-6,42804,9741,1580296
Other Short Term Loans 230,80200000000000000
Long term loans22,110,5870-1,091,158-2,004,856-3,598,1581,695,0973,437,075590,000972,000000000
Hire Purchase and Lease Commitments-46,594-234,200-277,769-335,423-286,210860,305269,67350,000-5,358-16,2236,33645,245-2,028-26,41828,446
other long term liabilities0-424,792424,792000-356,000241,000-330,508-384,000829,5080000
share issue00-2,801,1810-4,519,227-445,776-2,228,70904251000022,639,189
interest-2,165,088-511,161-658,015-720,919-823,116-754,054-750,260-719,000-622,000-721,949-627,489-664,177-670,620-666,526-720,678
cash flow from financing-12,028,124-7,017,388-5,250,226-1,585,21228,548,199-317,9082,038,259165,00018,559-1,128,599208,355-613,958-671,490-692,94421,947,253
cash and cash equivalents
cash-554,6471,630,482-4,167,9674,347,656-813,248-1,734,783-642,7992,652,000-7,243,9773,320,2452,398,3911,224,848538,361-586,3912,230,523
overdraft00000-30,132,528-953,4726,273,000-5,686,9404,913,1642,617,194-1,294,464-3,144,7156,492,24620,916,515
change in cash-554,6471,630,482-4,167,9674,347,656-813,24828,397,745310,673-3,621,000-1,557,037-1,592,919-218,8032,519,3123,683,076-7,078,637-18,685,992

P&L

August 2023

turnover

248m

+19%

operating profit

15.2m

+184%

gross margin

19.4%

+22.51%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

August 2023

net assets

37.8m

+0.33%

total assets

102.4m

+0.06%

cash

2.6m

-0.18%

net assets

Total assets minus all liabilities

sigma pharmaceuticals plc company details

company number

01561802

Type

Public limited with Share Capital

industry

46460 - Wholesale of pharmaceutical goods

incorporation date

May 1981

age

43

accounts

Group

ultimate parent company

None

previous names

roxburghe exports limited (November 1986)

incorporated

UK

address

fifth floor watson house, 54-60 baker street, london, W1U 7BU

last accounts submitted

August 2023

sigma pharmaceuticals plc Charges & Mortgages

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We found 18 charges/mortgages relating to sigma pharmaceuticals plc. Currently there are 2 open charges and 16 have been satisfied in the past.

charges

sigma pharmaceuticals plc Companies House Filings - See Documents

datedescriptionview/download